Role of integrin VLA-6 in suppression of bone formation in myeloma
整合素VLA-6在抑制骨髓瘤骨形成中的作用
基本信息
- 批准号:9206148
- 负责人:
- 金额:$ 37.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-01 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdipocytesAlpha CellAntibodiesAntigensAreaBindingBone DiseasesBone MarrowBone ResorptionCaringCell Adhesion MoleculesCell Differentiation processCell surfaceCellsClinicalClonal ExpansionCoculture TechniquesDefectDepositionDevelopmentDiabetes MellitusDiseaseEquilibriumFoundationsGoalsIn VitroInjectableIntegrin alpha6Integrin alpha6beta1IntegrinsKnowledgeLesionLigandsMAP Kinase GeneMAPK14 geneMalignant - descriptorMediatingMesenchymal Stem CellsMetastatic breast cancerMultiple MyelomaMusNewly DiagnosedNon-MalignantObesityOsteoblastsOsteoclastsOsteogenesisPatientsPlasma CellsQuality of lifeRoleSignal PathwaySignaling MoleculeSiteTestingTherapeuticWorkadipocyte differentiationbeta cateninboneclinically relevanteffective therapyhealingimprovedinnovationlipid biosynthesisnovelnovel strategiesosteoblast differentiationpalliativepublic health relevancetumor
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to investigate the mechanism by which myeloma cells alter the balance of adipogenesis and osteoblastogenesis, thereby suppressing bone formation. Multiple myeloma is characterized by a clonal expansion of malignant plasma cells. Bone destruction is a hallmark of this disease, and has a severe impact on patients' quality of life and survival. Unfortunately, current treatment only offers moderate palliative effects, and bone disease associated with myeloma remains incurable. The bone changes in myeloma patients results from increased osteoclast-mediated bone resorption and decreased osteoblast-mediated bone formation. In particular, new bone formation that usually occurs at sites of previously resorbed bones is deeply suppressed; as a result areas of bone destruction rarely heal. Previous studies have shown that myeloma cells inhibit osteoblast differentiation from mesenchymal stem cells (MSCs) by myeloma cells produce dickkopf-1, which can suppress Wnt/beta-catenin signaling pathway. However, the role of dickkopf-1 in suppressed bone formation remains controversial, because myeloma cells alone do not produce sufficient dickkopf-1 to suppress osteoblast differentiation, and administration of anti-dickkopf-1
antibody in patients failed to completely restore new bone formation, indicating there must be an additional mechanism for inhibition of osteoblast differentiation seen in myeloma. We observed that myeloma patients and myeloma-bearing mice had not only decreased osteoblastic deposits but also increased adipocytic deposits in bone marrow. In vitro co-culture of MSCs with myeloma cells not only inhibited osteoblast but also enhanced adipocyte differentiation. We further identified that integrin alpha-6 in myeloma cells is a novel factor to regulate adipocyte and osteoblast differentiation. Alpha-6 can bind with alpha-1 to form the integrin very late antigen-6, a cell surface heterodimer highly expressed in myeloma cells. We observed that p38 MAPK, a signaling pathway that is shown to inhibit osteoblastogenesis, upregulated alpha-6 expression. Blocking alpha-6 by an antibody significantly reduced adipocyte but enhanced osteoblast differentiation. We therefore hypothesize that myeloma cell alpha-6 enhances adipocyte differentiation, as a result less MSC differentiation into osteoblasts and less new bone formation. We propose to determine the role and mechanism of alpha-6 in adipogenesis and osteoblastogenesis, and develop the novel strategies to enhance bone formation by targeting alpha-6 and the related signaling molecules. The knowledge gained with the successful completion of the proposed work will provide a rationale for a therapeutic to enhance bone formation, filling in the defects caused by myeloma-induced osteoclast-mediated resorption. Of equal importance, as the increased adipocytic deposit is also found in bone marrow of patients with bone-metastatic breast cancer and non-malignant diabetes mellitus and obesity, the proposed work may have direct relevance to reduced bone formation observed in these diseases, and targeting alpha-6 may prove to be a novel approach in treating these patients also.
描述(由申请人提供):该项目的目标是研究骨髓瘤细胞改变脂肪生成和成骨细胞生成的平衡,从而抑制骨形成的机制。多发性骨髓瘤的特征是恶性浆细胞的克隆性扩张。不幸的是,目前的治疗只能提供中等的姑息效果,并且与骨髓瘤相关的骨病仍然无法治愈。骨髓瘤患者的骨吸收变化是由破骨细胞介导的骨吸收增加和成骨细胞介导的骨形成减少造成的,特别是,通常发生在先前骨吸收部位的新骨形成受到严重抑制,因此骨破坏区域很少愈合。研究表明,骨髓瘤细胞通过产生dickkopf-1来抑制骨髓瘤细胞向间充质干细胞(MSCs)分化,从而抑制Wnt/β-catenin信号通路的作用。 dickkopf-1 在抑制骨形成中的作用仍然存在争议,因为单独的骨髓瘤细胞不能产生足够的 dickkopf-1 来抑制成骨细胞分化,并且给予抗 dickkopf-1
患者体内的抗体未能完全恢复新骨形成,这表明在骨髓瘤中一定存在抑制成骨细胞分化的额外机制,我们观察到骨髓瘤患者和患有骨髓瘤的小鼠不仅骨中的成骨细胞沉积减少,而且骨中的脂肪细胞沉积增加。骨髓瘤细胞与间充质干细胞的体外共培养不仅抑制了成骨细胞,而且还增强了骨髓瘤细胞中的整合素α-6。调节脂肪细胞和成骨细胞分化的新因子。α-6 可以与 α-1 结合形成整合素极晚期抗原 6,这是一种在骨髓瘤细胞中高度表达的细胞表面异二聚体。为了抑制成骨细胞生成,通过抗体阻断 α-6 显着减少脂肪细胞,但增强成骨细胞分化,因此我们认为骨髓瘤细胞 α-6 增强脂肪细胞分化。我们建议确定α-6在脂肪生成和成骨细胞生成中的作用和机制,并开发通过靶向α-6和相关信号分子来增强骨形成的新策略。成功完成拟议工作将为增强骨形成的治疗提供理论依据,填补骨髓瘤诱导的破骨细胞介导的吸收引起的缺陷同样重要,因为脂肪细胞沉积也增加。骨转移性乳腺癌、非恶性糖尿病和肥胖症患者的骨髓,拟议的工作可能与这些疾病中观察到的骨形成减少直接相关,而靶向 alpha-6 可能被证明是治疗这些疾病的一种新方法病人也。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jing Yang其他文献
Jing Yang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jing Yang', 18)}}的其他基金
Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis
开发 Pleckstrin-2 小分子抑制剂来治疗血栓形成
- 批准号:
10545992 - 财政年份:2022
- 资助金额:
$ 37.02万 - 项目类别:
Functional interplay between Hippo and estrogen receptor ESR1
Hippo 和雌激素受体 ESR1 之间的功能相互作用
- 批准号:
10573162 - 财政年份:2022
- 资助金额:
$ 37.02万 - 项目类别:
Apical-basal polarity in tumor progression and metastasis
肿瘤进展和转移中的顶底极性
- 批准号:
10468642 - 财政年份:2019
- 资助金额:
$ 37.02万 - 项目类别:
Apical-basal polarity in tumor progression and metastasis
肿瘤进展和转移中的顶底极性
- 批准号:
10228549 - 财政年份:2019
- 资助金额:
$ 37.02万 - 项目类别:
Apical-basal polarity in tumor progression and metastasis
肿瘤进展和转移中的顶底极性
- 批准号:
10677660 - 财政年份:2019
- 资助金额:
$ 37.02万 - 项目类别:
Regulation of Tumor Invasion and Metastasis by Matrix Stiffness
基质硬度对肿瘤侵袭和转移的调节
- 批准号:
10374409 - 财政年份:2015
- 资助金额:
$ 37.02万 - 项目类别:
相似国自然基金
Alpha-catenin对视觉经验依赖的放射胶质细胞增殖调控的研究
- 批准号:31701189
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
HIF-1α对IgG免疫复合物诱导巨噬细胞炎症反应的调控作用
- 批准号:31400751
- 批准年份:2014
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
阿尔法-突触核蛋白积聚的分子机制及其细胞毒性
- 批准号:30570377
- 批准年份:2005
- 资助金额:8.0 万元
- 项目类别:面上项目
相似海外基金
Fatty Acid Signaling via GPCRs in Primary Cilia Controls Adipogenesis and Insulin Secretion, Regulating Obesity and Diabetes
原发纤毛中 GPCR 的脂肪酸信号控制脂肪生成和胰岛素分泌,调节肥胖和糖尿病
- 批准号:
10318656 - 财政年份:2020
- 资助金额:
$ 37.02万 - 项目类别:
Fatty Acid Signaling via GPCRs in Primary Cilia Controls Adipogenesis and Insulin Secretion, Regulating Obesity and Diabetes
原发纤毛中 GPCR 的脂肪酸信号控制脂肪生成和胰岛素分泌,调节肥胖和糖尿病
- 批准号:
10531880 - 财政年份:2020
- 资助金额:
$ 37.02万 - 项目类别:
Thy1 expression, adpogenesis, inflammation and orbital remodeling mechanisms in Thyroid Eye Disease
甲状腺眼病中 Thy1 表达、脂肪生成、炎症和眼眶重塑机制
- 批准号:
9213038 - 财政年份:2017
- 资助金额:
$ 37.02万 - 项目类别:
Effects of Age-Related Changes in the Microenvironment on Patterns of Hematopoiesis
与年龄相关的微环境变化对造血模式的影响
- 批准号:
9364678 - 财政年份:2017
- 资助金额:
$ 37.02万 - 项目类别: